丙氨瑞林与DDP对卵巢癌耐药细胞CoC1/cDDP凋亡的影响

目的 探讨促性腺激素释放激素类似物(GnRHa)丙氨瑞林(Alarelin)与顺铂(DDP)对人卵巢癌耐药细胞CoC1/cDDP凋亡的影响.方法 CoC1/cDDP细胞分别加入不同浓度的丙氨瑞林及DDP+丙氨瑞林培养,设空白对照组(不加药),流式细胞仪检测亚G1期细胞及凋亡细胞和线粒体膜电位(ΔΨm),半定量RT-PCR法检测CoC1/cDDP细胞生存素(survivin)-⊿Ex3 mRNA及天冬氨酸特异性半胱氨酸蛋白酶(caspase-3 mRNA的表达.采用四甲基偶氮唑蓝(MTT)法测定各组细胞生长抑制率.结果 ①随DDP浓度增加,亚G1期细胞及AnnexinV+/PI-细胞比例上升,对细胞的抑制作用增强(P＜0.05).丙氨瑞林作用于卵巢癌耐药细胞CoCl/cDDP后,随浓度增加降低ΔΨm,亚G1期细胞及AnnexinV+/PI-细胞比例增加,凋亡细胞增多,细胞增殖抑制率上升(P＜0.01).联合应用丙氨瑞林及10 μg/ml DDP后,线粒体膜电位(ΔΨm)降低,Rh123-细胞数增加,G1期细胞及AnnexinV+/PI-细胞增多,细胞抑制率明显上升,强于单用DDP或丙氨瑞林；②丙氨瑞林单独或联合DDP作用于CoCl/cDDP细胞,caspase-3mRNA的表达随丙氨瑞林浓度增加而上调,但survinin-⊿ Ex3 mRNA表达无明显变化(P＞0.05).结论 丙氨瑞林能促进凋亡,逆转CoCl/cDDP细胞对DDP耐药,其机制可能与降低ΔΨm,上调caspase-3mRNA表达有关.     

甲羟孕酮对人卵巢癌耐顺铂SKOV3/DDP细胞株放射敏感性的影响

目的 研究人卵巢癌耐顺铂SKOV3/DDP细胞株对放射治疗的影响,及应用醋酸甲羟孕酮( Medroxyprogesterone Acetate,MPA)于SKOV3/DDP细胞株,探讨其对放射敏感性的影响及其可能机制。方法 以人卵巢癌SKOV3细胞株及其耐顺铂SKOV3/DDP细胞株为研究对象接受不同剂量的放射线照射,采用MTT法、克隆形成实验分析细胞相对存活率及放射抗拒性;应用非细胞毒性剂量MPA联合不同剂量放射线照射于SKOV3/DDP细胞,同法测定联合MPA作用后SKOV3/DDP细胞放射敏感性的变化,采用 Sigma Plot 10.0版软件,利用多靶单击模型S =1-(1-eD0/D)n拟合细胞存活曲线,计算放射相关参数。并采用流式细胞技术 (FCM) 检测细胞周期及凋亡情况。结果 随着放射剂量增大,SKOV3细胞和SKOV3/DDP细胞的相对存活率下降,以SKOV3细胞明显;二者的平均致死剂量(D0)分别为3.186和7.794,D0越大,放射抗拒性越强,表明耐药SKOV3/DDP细胞的放射抗拒性强于SKOV3细胞;同法测定MPA联合放疗组细胞的克隆形成率明显低于单纯放疗组,二者D0分别为4.040、7.794,放射增敏比为1.929。MPA联合放疗作用于SKOV3/DDP细胞,使其细胞周期阻滞于G0/G1期,S期细胞比例下降,并可以增加耐药细胞的凋亡率。结论 人卵巢癌SKOV3/DDP细胞具有放化疗交叉耐受性;MPA可以逆转SKOV3/DDP细胞对放射的抗拒性,其可能机制为促进细胞的凋亡,阻滞细胞周期进程。     

p21~(WAF1/CIP1)和P53蛋白在子宫平滑肌肿瘤的表达和意义

目的 :探讨p2 1WAF1/CIP1和P5 3蛋白在子宫平滑肌肿瘤 (USMTs)的表达和意义。方法 :应用免疫组织化学法检测 2 0例普通型子宫平滑肌瘤 (UL) ,18例子宫平滑肌肉瘤 (LMS)及 70例交界性子宫平滑肌瘤 (BLM) :包括 4 0例富于细胞型子宫平滑肌瘤 (CL)、13例奇异型子宫平滑肌瘤 (BL)、4例核分裂活跃型子宫平滑肌瘤 (ML)、10例不典型子宫平滑肌瘤 (AL)及 3例恶性潜能未定型子宫平滑肌瘤 (STUMP)的p2 1WAF1/CIP1和P5 3蛋白的表达。结果 :LMS组p2 1WAF1/CIP1蛋白表达阳性率明显高于UL组 (P <0 .0 1)和BLM组 (P<0 .0 1) ;LMS组P5 3蛋白表达阳性率显著高于UL组 (P <0 .0 1)和BLM组 (P <0 .0 1)。结论 :LMS的发病机制涉及P5 3基因功能的丧失 ;p2 1WAF1/CIP1在USMT细胞的增殖和灭活中可能起到不同的作用     

Survivin反义寡核苷酸诱导人卵巢癌耐药细胞株COC_1/DDP凋亡的实验研究

目的 :探讨经脂质体介导的survivin反义寡核苷酸诱导人卵巢癌耐药细胞株COC1/DDP凋亡的作用。方法 :将脂质体介导的survivin反义寡核苷酸 (survivin ASONs)作用于COC1/DDP细胞 ,采用一步法RT PCR检测survivin、bcl 2mRNA的表达 ,并进行细胞核DNA梯形电泳 ,检测caspase 3活性 ,流式细胞仪检测细胞凋亡率及细胞周期。结果 :经survivin ASONs作用后COC1/DDP细胞中survivin等抗凋亡基因的表达下降 ,细胞核DNA电泳呈现凋亡细胞特有的梯状条带 ,caspase 3活性增加且呈时间依赖性 ,细胞凋亡率达33.18% ,细胞周期G2 /M及S期明显下降而多阻滞于G0 /G1期 ,与对照组差异有显著性(P <0 .0 5 )。结论 :survivin ASONs反义寡核苷酸能诱导人卵巢癌耐药细胞株COC1/DDP细胞凋亡 ,且效果显著     

米非司酮对卵巢上皮性癌耐药细胞DNA修复基因表达和顺铂敏感性的影响

目的 研究米非司酮对卵巢上皮性癌(卵巢癌)耐药细胞DNA修复基因表达的调控,及对顺铂的增敏作用.方法 应用四甲基偶氮唑蓝比色法检测2.5、5.0、10.0 μmol/L米非司酮作用后卵巢癌顺铂耐药细胞株COC1/DDP的顺铂半数抑制浓度(IC50);用RT-PCR技术、流式细胞仪检测米非司酮联合顺铂作用后COC1/DDP细胞ERCC1、BRCA1、hMLH1 mRNA的表达水平及细胞周期和凋亡率的变化;建立COC1/DDP细胞裸鼠皮下移植瘤模型,分为顺铂组、米非司酮组、联合组和对照组,观察米非司酮在裸鼠体内对顺铂的增敏作用.结果 2.5、5.0、10.0 μmol/L米非司酮分别使COC1/DDP细胞对顺铂的IC50下降为(3.18±0.46)、(1.95±0.14)和(0.64±0.18)μg/ml,2.5 μmol/L米非司酮联合顺铂作用后的IC50与单用顺铂者[(3.71±0.38)μg/ml]比较,差异无统计学意义(P=0.076),其他浓度之间两两比较,差异均有统计学意义(P＜0.01).米非司酮下调ERCC1、BRCA1、hMLH1 mRNA表达水平,3种基因mRNA的相对表达量随米非司酮浓度的升高均呈下降趋势.2.5、5.0、10.0 μmol/L米非司酮联合顺铂对COC1/DDP细胞作用后,G0/G1,期细胞比例升高(分别为51.68%、53.74%、55.08%).2.5、5.0、10.0 μmol/L米非司酮与10 μg/ml顺铂联合作用使细胞凋亡率分别增加为5.11%、9.13%和12.24%.米非司酮联合顺铂治疗裸鼠皮下移植瘤的生长抑制率为70.1%,与顺铂组、米非司酮组(分别为22.5%、6.5%)比较,差异均有统计学意义(P＜0.05).结论 米非司酮通过下调ERCC1、BRCA1、hMLH1基因的表达及阻滞G0/G1期细胞、增加细胞凋亡率来增强顺铂对卵巢癌细胞的抗肿瘤敏感性.     

丙戊酸钠协同顺铂对HO8910细胞杀伤作用机制研究

目的:探讨丙戊酸钠(VPA)协同顺铂(DDP)对人卵巢癌HO8910细胞的杀伤作用及机制。方法:以1μg/m l DDP联合3mmol/L VPA处理细胞,MTT法检测细胞生长抑制率;光镜下观察药物作用下各组细胞形态学的改变;流式细胞术检测细胞周期阻滞情况;RT-PCR法检测p53、p21 mRNA水平表达的改变;W estern blot法检测Ac-H3、p53、p21、Cyclin D1蛋白水平表达的改变。结果:(1)VPA能明显抑制HO8910细胞生长,且呈剂量和时间依赖性,VPA+DDP处理组抑制率高于DDP处理组,组间差异有统计学意义(P<0.05);(2)光镜下观察细胞形态,可见VPA处理组细胞体积缩小呈长梭型,胞膜皱缩,贴壁不良,VPA+DDP组改变更明显;(3)VPA阻滞卵巢癌HO8910细胞周期于G0/G1期,VPA+DDP组S期细胞明显减少;(4)VPA及VPA联合DDP均能够明显提高卵巢癌HO8910细胞组蛋白H3的乙酰化水平,上调p53、p21 mRNA及蛋白表达水平,降低CyclinD1蛋白的表达水平,组间差异有统计学意义(P<0.05)。结论:VPA能够协同DDP杀伤卵巢癌细胞HO8910;其作用机制可能与VPA提高组蛋白乙酰化水平,上调p53、p21基因表达和下调Cyclin D1表达,引发细胞周期阻滞有关。     

子宫内膜癌顺铂耐药细胞株的建立和鉴定及耐药机制研究

目的 建立子宫内膜癌顺铂耐药细胞株ISH/DDP,鉴定其生物学特性,并探讨其顺铂耐药的机制.方法 采用顺铂浓度逐步递增联合大剂量顺铂冲击方法,在体外连续诱导、培养子宫内膜癌细胞株Ishikawa细胞,建立子宫内膜癌顺铂耐药细胞株ISH/DDP.非放射性细胞增殖法(MTS法)测定ISH/DDP细胞对顺铂的耐药指数;绘制细胞生长曲线,计算细胞群体倍增时间;流式细胞术检测ISH/DDP细胞的细胞周期比例;免疫细胞化学法检测ISH/DDP细胞中耐药蛋白--乳腺癌耐药蛋白(BCRP)、P糖蛋白(P-gp)以及谷胱甘肽S转移酶π(GST-π)蛋白的表达水平,以综合积分表示.结果 Ishikawa细胞在体外采用顺铂浓度逐步递增联合大剂量顺铂冲击方法 连续诱导、培养,历时10个月,成功建立了子宫内膜癌顺铂耐药细胞株ISH/DDP,其耐药指数为3.77.Ishikawa细胞和ISH/DDP细胞的群体倍增时间分别为34.1 h和40.4 b,两者比较,差异有统计学意义(P<0.05).与Ishikawa细胞相比,ISH/DDP细胞的S期细胞比例[分别为(44.2±6.1)%和(55.3±8.4)%]增加,G2/M期细胞比例[分别为(11.9±0.7)%和(5.7±2.4)%]减少,差异均有统计学意义(P<0.05);G0/G1期细胞比例[分别为(44.3±5.7)%和(39.0±10.7)%]减少,但差异无统计学意义(P>0.05).ISH/DDP细胞中BCRP蛋白的表达水平为(16.3±2.0)分,高于Ishikawa细胞的(13.4±1.5)分,差异有统计学意义(P<0.05);而Ishikawa和ISH/DDP细胞中P-gp蛋白的表达水平分别为(16.1±1.0)和(15.5±1.2)分,GST-π蛋白的表达水平分别为(14.9±1.1)和(15.2±1.9)分,分别比较,差异均无统计学意义(P>0.05).结论 ISH/DDP细胞具有耐药表型及耐药细胞的生物学特性;其耐药机制可能与细胞中BCRP蛋白的过度表达相关.

Abstract：

Objective To establish the cisplatin(DDP)-resistant cell line from human endometrial cancer cell line Ishikawa and to investigate its resistant mechanism to DDP. Methods A resistant endometrial cancer cell line ISH/DDP was established by gradually increasing dose of cisplatin and high-dose stimulation. The resistant index was estimated by 3-(4,5-dimethylthiazol-zyl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium,inner salt (MTS) assay. Cell growth curve, doubling time and cell cycle phase distribution were measured; drug-resistant protein of breast cancer resistance protein (BCRP),P-glycoprotein (P-gp) and glutathione-S-transferase-π (GST-π) were examined by immuocytochemistry. Results The DDP-resistant cell line ISH/DDP was established with the resistant index of 3. 77. The proliferation of ISH/DDP got slow, doubling time prolonged, which were 40. 1 hours, while it was 34. 1 hours in Ishikawa (P<0.05); and the cell number of G0/G1 phase [(44. 3 ±5. 7)% and (39. 0 ± 10. 7)% ,P >0. 05] and G2/M phase [(11.9 ±0.7)% and (5. 7 ±2. 4)% ,P <0. 05] decreased, while S-phase [(44. 2 ±6.1)% and (55. 3 ± 8. 4) % , P < 0. 05] increased compared with parent cells. The comprehensive score of the expression of BCRP in ISH/DDP was 16. 3 ± 2. 0, while it was 13.4 ± 1. 5 in Ishikawa (P < 0. 05). The score of the expression of P-gp in ISH/DDP and Ishikawa were 15. 5 ± 1. 2 and 16. 1 ± 1. 0 (P > 0. 05) ,respectively. The score of the expression of GST-π in ISH/DDP and Ishikawa were 15. 2 ± 1. 9 and 14. 9 ± 1.1 (P > 0. 05) . Conclusion ISH/DDP cell line showed a typical resistant phenotype and biological characteristics, which may be accounted for high BCRP expression.     

JAK抑制剂AG490联合DDP对宫颈癌裸鼠移植瘤生长的影响

目的:观察JAK/STAT通路阻断剂AG490联合顺铂(Cis-diaminedichloro-platinum,DDP)对宫颈癌裸鼠移植瘤生长的影响,探讨AG490通过阻断STAT3通路对人宫颈癌裸鼠移植瘤生长抑制作用及与caspase-3蛋白表达的关系。方法:建立人子宫颈癌(HeLa)细胞裸鼠异种移植瘤模型并分组。AG490单用或联合DDP处理各组裸鼠。用药期间测量裸鼠体重和肿瘤体积,检测瘤重计算抑瘤率。流式细胞术检测肿瘤组织中细胞凋亡情况,免疫组化检测移植瘤组织中P-STAT3和caspase-3蛋白表达。数据均用SPSS10.0统计软件处理。结果:治疗第7天与DDP组(265.51±23.74)和AG490组(382.89±16.54)比,联合用药组(250.66±18.55)肿瘤体积明显缩小(P<0.05和P<0.001)。DDP组裸鼠体重与联合用药组差异有统计学意义(P<0.05)。对照组、DDP组、AG490组和联合用药组抑瘤率分别为0,51.2%,33.6%,59.2%,联合用药组的抑瘤作用比单用组更加明显(P<0.05,P<0.001)。FCM分析表明,实验组的肿瘤标本中均可见凋亡峰,凋亡率分别是(52.1±1.3)%,(39.5±0.4)%和(66.7±1.8)%,与对照组(10.2±2.4)%的差异有统计学意义(P<0.05)。肿瘤坏死范围与用药明显相关,联合用药组肿瘤的坏死范围最大,与单独用药组的差异有统计学意义(P<0.05)。免疫组化结果显示,联合用药组P-STAT3表达下调,caspase-3表达上调,但二者无负相关(r=-0.074,P>0.05)。结论:AG490对宫颈癌生长有一定的抑制作用,增加P-STAT3表达,但对caspase-3表达无直接作用。AG490与DDP联合应用可进一步提高治疗效果。     

白细胞介素-15治疗3AO裸鼠移植瘤的实验研究

目的:探讨白细胞介素-15(IL-15)治疗3AO裸鼠皮下移植瘤的效果及其机制。方法:建立3AO裸鼠皮下移植瘤模型,随机分为5组,每组12只。I组为顺铂(cD-DP)3mg/kg;Ⅱ组、Ⅲ组分别为IL-1550μg/kg,100μg/kg;Ⅳ组为cDDP1.5mg/kg加IL-1550μg/kg;Ⅴ组为对照组,注射生理盐水(各组药物均腹腔注射,按每只裸鼠0.2ml配制),1次/d,连用1周。观察移植瘤成瘤率、裸鼠生存期、生存延长率及肿瘤生长曲线。停药1天,1周,2周后,观察移植瘤细胞凋亡率及细胞周期,NK细胞群计数;测定裸鼠脾脏重量;对移植瘤及裸鼠肝、脾、肾行常规病理学检查。结果:实验组与对照组相比荷瘤裸鼠生存延长率,脾脏重量,移植瘤细胞凋亡率,NK细胞群计数均有明显差异。病理学检查示各治疗组均见肿瘤坏死,肿瘤细胞周围及肿瘤内淋巴细胞明显浸润。IL-15治疗组脾脏有充血增生表现,肝脏肝细胞嗜酸性变性,肝细胞水肿,周围有浊肿;cDDP治疗组肾脏近曲小管和远曲小管细胞水肿,管腔变小;对照组裸鼠肝、脾、肾未见明显病理改变。结论:IL-15对人卵巢癌裸鼠皮下移植瘤有明显的抑制作用,其机制可能与IL-15增强NK细胞的细胞毒活性,诱导NK细胞及细胞因子产生有关。     

米非司酮对子宫内膜癌细胞株HHUA裸鼠移植瘤生长及survivin、caspase-3的影响

目的:研究米非司酮(mifeprisitone,MIF)对子宫内膜癌细胞系HHUA裸鼠移植瘤生长的抑制作用及对survivin、caspase-3的影响。方法:体外培养子宫内膜癌HHUA细胞接种裸鼠皮下建立裸鼠移植瘤动物模型,随机将20只移植瘤荷瘤裸鼠分为两组,分别用MIF、精制花生油治疗6周。观察治疗前后移植瘤体积的变化。HE染色观察肿瘤组织的病理变化。免疫组织化学染色法检测移植瘤组织survivin表达,Image-proplus 4．1．00软件分析系统进行染色结果半定量分析,应用RT-PCR方法检测肿瘤组织survivin、caspase-3的mRNA表达,并用Alphalmager 2200系统进行分析。结果:MIF组移植瘤体积115．25±10．97mm~3,对照组移植瘤体积313．25±43．92mm~3,二者差异有统计学意义(P＜0．01);HE染色示MIF组移植瘤坏死面积较对照组显著增加;MIF组survivin HSCOREs为85．9±11．2,对照组207．6±39．6,两者差异有统计学意义(P＜0．01);MIF组survivin mRNA光密度比值为1．65±0．17,对照组2．75±0．23,两者差异有统计学意义(P＜0．01);MIF组caspase-3的mRNA光密度比值为3．98±0．32,对照组2．12±0．25,两者差异有统计学意义(P＜0．01)。结论:MIF具有抑制子宫内膜癌裸鼠移植瘤生长的作用;其机制可能与下调survivin、上调caspase-3表达有关。     

In vitro study of the influence of GST-π gene transfer on drug-resistance of human cord blood CD34~+ cells

Chemotherapyremainsthemosteffectiveandusedtreatmentfordisseminatedneoplasms[1,2 ] .However ,theefficacyofmanychemotherapeuticagentsislimitedbytheirtoxicityonnormaltissues ,resultinginnarrowthera peuticindex .Myelosuppressionisthemostfrequentacutedose limitingsideeffectresponsiblefordelaysinchemotherapyadministrationordoseattenuationwithde creasedantitumourresponse .Anattractivestrategytodecreasehematopoietictoxic ityofchemotherapeuticagentsistoincreasechemoresis tanceofhematopoieticstemcellsan…     

Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma

OBJECTIVE: Adenocarcinoma of the uterine cervix appears to be increasing in prevalence and it has been suggested that these tumors tend to be less sensitive to radiation therapy and to chemotherapy than squamous carcinomas. In the present study, 29 patients with locally advanced cervical adenocarcinoma (bulky IB-IVB) were treated with neoadjuvant chemotherapy (NAC) using cisplatin, aclacinomycin-A and mitomycin-C, followed by radical surgery or irradiation. METHODS: To predict the prognosis and response to the chemotherapy, the expression of apoptosis associated-proteins, p53, p21WAF1/CIP1, Bcl-2 and activated caspase-3 was evaluated for tumor samples by immunohistochemistry. RESULTS: Of the analyzed clinicopathological factors, the overexpression of p53 was frequently observed in endocervical-type adenocarcinoma, nonresponders to chemotherapy and the grade 0 histologic effect of the chemotherapy. Positive staining of Bcl-2 was frequently observed in the early stage and had a better prognosis than for patients with the negative staining; however, there was no correlation between responders and nonresponders to chemotherapy. The expression of p21WAF1/CIP1 and caspase-3 was not correlated to the clinicopathological factors. CONCLUSION: In this study, the overexpression of p53 was found to be a factor to predict the chemoresistance and positive expression of Bcl-2 indicated as a better prognostic value. For p21WAF1/CIP1 and caspase-3, further analysis is necessary.     

人卵巢上皮性癌顺铂耐药细胞系3AO/cDDP模型的建立及耐药机理的实验研究

目的：模拟临床卵巢上皮性癌化疗的用药特点建立顺铂耐药细胞系3AO／CDDP,检测LRP、MRP、P－gp、GSTπ和TopeⅡ表达。方法：以临床卵巢上皮性癌化疗用药的最低剂量换算终浓度,采用大剂量顺铂（10μg／ml）反复间歇24h暴露法建立顺铂耐药细胞系;用FCM法检测LRP、MRP、P－gp、GSTπ和TopoⅡ表达。结果：历时4．5个月建成顺铂耐药株3AO／cDDP,耐药性稳定,耐药指数1．62,与临床耐药倍数相近。3AO／cDDP细胞MRP、P－gp表达与3AO相比无明显变化（P＞0．05）,LPR、GSTπ表达明显升高（P＜0．005及P＜0．05）,Tope-Ⅱ含量明显降低（P＜0．05）。结论：3A0／cDDP是模拟临床用药特点建立的、研究顺铂耐药的理想模型;顺铂耐药与LRP、GSTπ表达升高及TopoⅡ含量降低有关,与MRP、P-gp无关。     

Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor

Purpose

The aim of this study was to investigate the effect of tamoxifen (TAM), methoxyprogesterone acetate (MPA) and their combined treatment on cisplatin-resistant ovarian cancer SKOV3/DDP cells, as well as the potential mechanisms.

Methods

MTT assay was used to investigate the effect of different concentrations (0.01, 0.1, 1, 10 and 100 μM) of TAM, MPA and their combined treatment on the proliferation of cisplatin-resistant ovarian cancer SKOV3/DDP cells. Flow cytometry was employed to analyze the cell cycle and apoptosis rate of SKOV3/DDP cells treated with medium concentration (10 μM) of TAM, MPA and their combined treatment. Change in the protein level of vascular endothelial growth factor (VEGF) in response to drug treatments was measured using Western-blot.

Results

The proliferation of SKOV3/DDP cells was inhibited by 1, 10 and 100 μM of TAM or MPA in a dose-dependent manner. Compared to the control group, 10 μM TAM could significantly arrest SKOV3/DDP cells in the G0/G1 stage and induce apoptosis (p < 0.01). However, 10 μM MPA only promoted cell apoptosis, while exhibited little effect on the cell cycle. We further found that 10 μM TAM could remarkably reduce the protein expression of VEGF, while 10 μM MPA only induce a slight reduction. Strikingly, the combined treatment of TAM and MPA exhibited additive effect on the proliferation, cell cycle, apoptosis rate and VEGF expression of SKOV3/DDP cells.

Conclusions

We found that TAM, MPA and their combined treatment exhibited significant inhibitory effect on the cisplatin-resistant ovarian cancer SKOV3/DDP cells. Hence, TAM and MPA could be potential cytotoxic drugs to treat cisplatin-resistant patients with advanced ovarian cancer.